UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 24, 2013

CATALENT PHARMA SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)

Delaware	333-147871	13-3523163
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

14 Schoolhouse Road Somerset, New Jersey	08873
(Address of registrant's principal executive office)	(Zip code)

(732) 537-6200
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On April 24, 2013, Catalent Pharma Solutions, Inc. (the "Company") will be making a slide presentation to existing and prospective lenders that discusses the potential entry into a new unsecured term loan facility, the proceeds of which would be used to redeem the outstanding $269.1 aggregate principal amount of the Company's 9.50%/10.25% Senior PIK-Election Notes due 2015. The lender presentation contains, among other things, selected preliminary unaudited financial results for the Company's three and twelve months ended March 31, 2013 and projected unaudited financial results for the Company's fiscal year ending June 30, 2013. Certain slides from the slide presentation are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated by reference herein. The slides contain statements intended as "forward-looking statements," all of which are subject to the cautionary statement about forward-looking statements set forth herein and therein.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Information set forth in this Current Report (including the exhibits and attachments hereto) contains forward-looking statements. These statements are not historical facts, but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. The Company's actual results and financial condition may differ, perhaps materially, from the anticipated results and financial condition in any such forward-looking statements and, accordingly, readers are cautioned not to place undue reliance on such statements. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The selected preliminary financial data for the Company's three and twelve months ended March 31, 2013 furnished in this Current Report (including the exhibits hereto) has been prepared by, and is the responsibility of, the management of the Company. The information and estimates have not been compiled or examined by the Company's independent auditors and are subject to revision as the Company prepares its financial statements as of and for the three and nine months ended March 31, 2013. Because the Company has not completed its normal quarterly closing and review procedures for the three months ended March 31, 2013, and subsequent events may occur that require adjustments to these results, there can be no assurance that the final results for the three and twelve months ended March 31, 2013 furnished in this Current Report (including the exhibits hereto) will not differ materially from these estimates. These estimates should not be viewed as a substitute for financial statements prepared in accordance with U.S. GAAP or as a measure of performance. In addition, these estimated results for the three and twelve months ended March 31, 2013 are not necessarily indicative of the results to be achieved for any future period.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following Exhibit is furnished as part of this Current Report on Form 8-K.

Exhibit No.	Description
99.1	Lender Presentation Slides dated April 24, 2013

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Catalent Pharma Solutions, Inc.
(Registrant)

By: /s/ Samrat S. Khichi
Name: Samrat S. Khichi
Title: Senior Vice President, Chief Administrative Officer, General Counsel and Secretary

Date: April 24, 2013

EXHIBIT LIST

Exhibit No.	Description
99.1	Lender Presentation Slides dated April 24, 2013

Exhibit 99.1

Catalent

Lender Presentation

MATTHEW WALSH
SVP FINANCE & CFO

April 2013

DEVELOPMENT DELIVERY SUPPLY

more products. better treatments. reliably supplied.™

Forward Looking Statements

This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as "believe," "expect," "anticipate", "intend", "estimate", "plan", "project", "foresee", "likely", "may", "will", "would" or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals, particularly regarding our future financial performance and prospects are, or may be, forward-looking statements.

These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent Pharma Solutions' expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; conditions in the credit markets and economic conditions generally, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs; and our ability to successfully integrate acquired businesses and realize any anticipated synergies and cost reductions. For a more detailed discussion of these and other factors, see the information under the caption "Risk Factors" in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent Pharma Solutions does not undertake any obligation to update any forward-looking statements as a result of new information or future events or developments unless required by law.

The selected preliminary financial data for the Company's three and twelve months ended March 31, 2013 included in this presentation has been prepared by, and is the responsibility of, the management of the Company. The information and estimates have not been compiled or examined by the Company's independent auditors and are subject to revision as the Company prepares its financial statements as of and for the three and nine months ended March 31, 2013. Because the Company has not completed its normal quarterly closing and review procedures for the three months ended March 31, 2013, and subsequent events may occur that require adjustments to these results, there can be no assurance that the final results for the three and twelve months ended March 31, 2013 included in this presentation will not differ materially from these estimates. These estimates should not be viewed as a substitute for financial statements prepared in accordance with U.S. GAAP or as a measure of performance. In addition, these estimated results for the three and twelve months ended March 31, 2013 are not necessarily indicative of the results to be achieved for any future period.

Non-GAAP Financial Measures

Management measures operating performance based on consolidated earnings from continuing operations before interest expense, expense/ (benefit) for income taxes and depreciation and amortization and adjusted for the income or loss attributable to non-controlling interest ("EBITDA from continuing operations"). EBITDA from continuing operations is not defined under U.S. GAAP and is not a measure of operating income, operating performance or liquidity presented in accordance with U.S. GAAP and is subject to important limitations.

We believe that the presentation of EBITDA from continuing operations enhances an investor's understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business and use this measure for business planning purposes. In addition, given the significant investments that we have made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that EBITDA from continuing operations will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. We present EBITDA from continuing operations in order to provide supplemental information that we consider relevant for the readers of the financial statements, and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of EBITDA from continuing operations may not be the same as similarly titled measures used by other companies.

In addition, the Company evaluates the performance of its segments based on segment earnings before minority interest, other (income) expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization ("Segment EBITDA").

Under the indentures governing our outstanding notes, our ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as "EBITDA" in the indentures). Adjusted EBITDA is based on the definitions in our indentures, is not defined under U.S. GAAP and is subject to important limitations. We have included the calculations of Adjusted EBITDA for the periods presented.

Adjusted EBITDA is the covenant compliance measure used in certain covenants under the indentures governing our notes, particularly those governing debt incurrence and restricted payments. Because not all companies use identical calculations, our presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies.

The most directly comparable GAAP measure to EBITDA from continuing operations and Adjusted EBITDA is earnings / (loss) from continuing operations. A reconciliation of earnings / (loss) from continuing operations to EBITDA from continuing operations to Adjusted EBITDA is included as an appendix to this presentation.

Capitalization

(US$ mm)	12/31/12 (1)	Adj.	As Adjusted
Cash	$70.2	1.8	$72.0
Revolver ($200mm, 2016)	–		–
Extended EUR Term Loan B (€206mm, 2016)	271.9		271.9
Extended USD Term Loan B (2016)	795.3		795.3
USD Term Loan C (2017)	649.3		649.3
New Unsecured Term Loan (2017)	–	275.0	275.0
Senior PIK Notes (2015)	269.1	(269.1)	–
Senior Notes (2018)	348.1		348.1
Senior Sub Notes (€215mm, 2017)	285.0		285.0
Other Debt (Incl. Capitalized Lease Oblig.)	81.4		81.4
Total Debt	**$2,700.1**		**$2,706.0**

Summary Credit Statistics	12/31/12 (1)		As Adjusted
Pro Forma Covenant Adjusted EBITDA (2)	$425.4		$425.4
Net Debt / Pro Forma Covenant Adjusted EBITDA (2)	**6.2x**		**6.2x**
Pro Forma Covenant Adj. EBITDA (2) / Cash Int. Exp.	**2.3x**		**2.4x**

Note: Financials assume Euro rate of 1.3226 for 12/31/2012 Euro denominated debt

(1) Pro forma for the February 2013 Term Loan repricing and refinancing
(2) Pro forma to give effect to the CTS Acquisition and German JV consolidation as if they had occurred on January 1, 2012; includes unrealized synergies and excludes discontinued operations

The Global Leader in Development Solutions & Advanced Delivery Technologies



(1) Pro Forma for full year contribution of Aptuit CTS acquisition and R.P. Scherer GmbH, including unrealized synergies

Broad and Diverse Revenue Streams

Geography



***80+
Countries***

Customer



***1,000+
Customers***

Product



***7,000+
Products,
None >3%
of Sales***

Offering



***Diverse
Markets and
Offerings***

Note: Revenue by Geography, Customer, Product and Offering shown above reflective of FY2012 revenues, and includes impact of Aptuit CTS since date of acquisition and excludes discontinued operations

Solid Financial Growth Since 2009





Management preliminarily estimates FY2013 reported EBITDA to be in the $407 – 415mm range; adjusted for unrealized synergies, the implied FY2013 Pro Forma Covenant Adjusted EBITDA range would be $420 – 428mm

Compound Annualized Revenue Growth of 6.1% since 2009; Adjusted EBITDA Margin Improvement of ~430bps

(1) Represents Pro Forma Covenant Adjusted EBITDA which gives effect to unrealized synergies associated with the Aptuit CTS Acquisition and German JV consolidation
(2) CAGRs represent as reported financials

Financial Momentum at Catalent

LTM Adjusted EBITDA (1)(2)
(US$ mm)



- Improved offering mix to higher margin (Oral Tech, Dev't & Clinical)
- Operating leverage enabled by functional re-alignment

Adjusted EBITDA up more than $130mm
Expanded Adj. EBITDA margin +330bps

(1) Historical financials shown pro forma for divestiture of Printed Components business in 4Q FY'11 and N.A. Commercial Packaging in 4Q FY'12; includes Aptuit CTS since inception (2/17/12)

(2) The Q3FY13 LTM Adjusted EBITDA includes an estimate of Q3FY13 Adjusted EBITDA of approximately $100 million. The estimated Adjusted EBITDA for the quarter is derived from an estimate of Earnings/(Loss) from continuing operations before tax of approximately ($18) million and has been adjusted to exclude approximately $54 million of interest expense, approximately $39 million of depreciation and amortization and approximately $25 million of adjustments pursuant to the terms of our indenture. The Company has not completed its normal quarterly closing and review procedures for the three months ended March 31, 2013. Therefore, because our income tax provision has not yet been determined, the reconciliation for Q3FY13 LTM Adjusted EBITDA begins with Earnings/(Loss) from continuing operations before tax

Catalent

Q&A



Pro Forma Covenant Adjusted EBITDA Reconciliation

(US$ mm)	PF LTM Ending 12/31/12
Earnings/(loss) from continuing operations	$(50.7)
Interest expense, net	207.1
Income tax (benefit)/expense	11.7
Depreciation and amortization	147.4
Non-controlling interest	(0.9)
EBITDA from continuing operations	**$314.6**
Equity compensation[(a)]	3.6
Impairment charges and (gain)/loss on sale of assets[(b)]	5.1
Financing related expenses[(c)]	10.9
U.S. GAAP Restructuring[(d)]	17.5
Acquisition, integration and other special items[(e)]	32.6
Property and casualty losses, net[(f)]	5.8
Foreign exchange loss/(gain) (included in other, net)	0.1
Other adjustments (Sponsor's fee, severance)[(g)]	14.2
Adjusted EBITDA	**$404.4**
Full year of CTS Acquisition ownership adjustments[(h)]	19.0
Fully consolidated contribution of joint venture[(i)]	2.0
Pro Forma Covenant Adjusted EBITDA	**$425.4**

(a) Reflects non-cash stock-based compensation expense under the provisions of ASC 718 Compensation Stock Compensation
(b) Reflects non-cash asset impairment charges and losses from the sale of assets not included in restructuring and other special items
(c) Reflects financing expenses related to refinancing activity
(d) Reflects U.S. GAAP restructuring charges which were primarily attributable to activities which focus on various aspects of operations, including consolidating certain operations, rationalizing headcount and aligning operations in a more strategic and cost-efficient structure to optimize our business
(e) Primarily reflects acquisition and integration related costs attributable to discrete transactions occurring during fiscal 2012 including the CTS Acquisition and the purchase of the remaining 49% non-controlling interest in our joint venture in Eberbach, Germany
(f) Primarily reflects property and casualty (gains)/losses resulting from fire damage to a U.K. packaging services operation and the associated insurance reimbursements
(g) Represents amount of sponsor advisory fee and certain severance costs not included in U.S. GAAP Restructuring
(h) Gives effect to the CTS Acquisition as if it had been completed on January 1, 2012 and includes unrealized synergies
(i) Reflects the minority share purchase of our majority-owned softgel joint venture in Germany as if it had been completed on January 1, 2012

Adjusted EBITDA Reconciliation

($ millions)	Sep 30, 2008	Dec 31, 2008	Mar 31, 2009	Jun 30, 2009	Sep 30, 2009	Dec 31, 2009	Mar 31, 2010	Jun 30, 2010	Sep 30, 2010	Dec 31, 2010	Mar 31, 2011	Jun 30, 2011	Sep 30, 2011	Dec 31, 2011	Mar 31, 2012	Jun 30, 2012	Sep 30, 2012	Dec 31, 2012
	Quarters Ended																	
Earnings / (Loss) from continuing operations	24.7	(89.5)	(134.1)	1.3	(235.0)	(15.6)	0.4	12.9	(27.0)	(1.3)	(3.7)	2.9	(6.8)	12.5	(2.7)	(0.9)	(19.5)	(27.6)
Interest expense, net	48.4	50.1	42.1	41.5	40.8	44.2	37.3	38.8	40.6	41.1	39.7	44.1	42.1	41.1	47.9	52.1	53.9	53.2
Income tax (benefit) / provision	(7.5)	6.7	3.7	14.0	(11.7)	19.5	7.7	6.4	1.4	9.2	7.6	5.6	3.5	7.3	8.2	(2.5)	(2.0)	8.0
Depreciation and Amortization	33.7	33.0	27.9	30.0	29.5	29.3	28.9	29.9	27.9	28.9	29.5	29.1	28.6	29.5	34.7	36.9	37.3	38.5
Noncontrolling interest	1.8	0.1	(0.7)	(0.6)	1.8	(0.9)	(1.2)	(2.3)	0.8	(1.5)	(1.8)	(1.4)	0.5	(0.8)	(0.9)	-	-	-
EBITDA from continuing operations	101.1	0.4	(61.1)	86.2	(174.6)	76.5	73.1	85.7	43.7	76.4	71.3	80.3	67.9	89.6	87.2	85.6	69.7	72.1
Non-cash stock compensation expense	1.4	1.0	0.2	(2.9)	(1.1)	1.3	1.0	1.4	1.4	1.0	0.9	0.7	0.9	0.8	0.9	1.1	1.0	0.6
Impairment charges and (gain)/loss on sale of assets	0.1	(0.2)	136.0	3.6	210.1	0.1	(0.2)	4.8	0.6	(0.5)	3.1	0.4	(0.4)	(0.4)	(0.6)	3.3	(0.2)	2.6
Financing related expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.9
US GAAP Restructuring	1.4	(0.1)	4.9	5.1	0.7	1.9	4.0	11.1	5.1	3.4	2.8	1.2	0.8	10.3	1.5	6.9	3.5	5.6
Acquisition, integration and other special items	-	-	-	4.6	1.2	3.5	5.1	1.8	2.6	1.7	4.1	6.0	4.6	4.1	14.3	10.1	4.8	3.4
Property and casualty losses	-	-	-	-	-	-	-	-	-	-	1.1	10.5	(0.5)	(14.1)	4.1	1.7	-	-
Foreign exchange (gain)/loss	(59.2)	63.9	(11.6)	(11.8)	31.1	(13.1)	0.1	(21.9)	10.6	1.5	11.2	2.2	5.3	(6.6)	(1.7)	(1.6)	0.2	3.2
Other (Sponsor's fee, severance)	4.6	2.2	6.2	(2.2)	2.0	3.2	2.8	2.5	2.5	2.5	2.5	3.1	2.9	2.8	2.9	4.7	3.3	3.3
Adjusted EBITDA, quarter	49.4	67.3	74.6	82.5	69.4	73.4	85.9	85.4	66.5	86.0	97.0	104.4	81.5	86.5	108.6	111.8	82.3	101.7
Estimated cost savings					-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjusted EBITDA - Trailing 12 months				273.8	293.8	299.9	311.2	314.1	311.2	323.8	334.9	353.9	368.9	369.4	381.0	388.4	389.2	404.4

Note: Historical financials shown pro forma for divestiture of Printed Components business in 4Q FY'11 and N.A. Commercial Packaging in 4Q FY'12; includes Aptuit CTS since inception (2/17/12)

Catalent